Humanin: A possible linkage between Alzheimer's disease and type 2 diabetes

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 543-552

  Mahboobi, Hamidreza ^a,b   Golmirzaei, Javad ^c   Gan, Siew H ^d   Jalalian, Mehrdad ^e   Kamal, Mohammad A ^f  

^a HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PAYAME NOOR UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^e King Fahd Medical Research Centre King Abdulaziz University ^*

^f KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alzheimer's disease; Amyloid beta; Apo lipoprotein e; Diabetes; Inflammation; Oxidative stress

Indexed keywords

ACETYLCHOLINESTERASE; ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLINESTERASE; GLYCOGEN SYNTHASE KINASE; HUMANIN; INSULIN RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; PRESENILIN; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MITOCHONDRIAL DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PATHOLOGY; PREVALENCE; RISK FACTOR; TREATMENT PLANNING; DIABETES MELLITUS, TYPE 2; GENETICS; METABOLISM;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXIDATIVE STRESS;

EID: 84904498123     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527312666131223110147     Document Type: Article

References (135)

1. Zhang R, Miller RG, Madison C, et al. Systemic immune system alterations in early stages of Alzheimer's disease. J Neuroimmunol 2013; 256(1-2): 38-42.
2. Diwan A, Aziz KS, Rishi P, et al. Spectrum from obesity to neurodegenerative disorder. Am J Neuroprot Neuroregen 2012; 4(1): 31-9.
3. Priyadarshini M, Kamal MA, Greig NH, et al. Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets 2012; 11(4): 482-9.
4. Zito G, Polimanti R, Panetta V, et al. Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia. Rejuvenation Res 2013; 16(1): 51-6.
5. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide islet amyloid and diabetes mellitus. Physiol Rev 2011; 91(3): 795-826.
6. Petersen KF, Dufour S, Morino K, et al. Reversal of muscle insulin resistance by weight reduction in young lean insulin-resistant offspring of parents with type 2 diabetes. Proc Natl Acad Sci USA 2012; 109(21): 8236-40.
7. Guzman-Flores JM, Escalante M, Sanchez-Corona J, et al. Association analysis between -308G/A and -238G/A TNF-alpha gene promoter polymorphisms and insulin resistance in Mexican women with gestational diabetes mellitus. J Investig Med 2013; 61(2): 265-9.
8. Salacz P, Csibri E. Diabetes mellitus and Alzheimer's disease. Orv Hetil 2011; 152(13): 512-5.
9. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the Risk of Dementia Alzheimer's Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002; 14(2): 77-83.
10. Allen KV, Frier BM, Strachan MWJ. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004; 490(1-3): 169-75.
11. Warren RE, Frier BM. Hypoglycaemia and cognitive function. Diabetes Obesity Metab 2005; 7(5): 493-503.
12. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5(1): 64-74.
13. Janson J, Laedtke T, Parisi JE, et al. Increased Risk of Type 2 Diabetes in Alzheimer Disease. Diabetes 2004; 53(2): 474-81.
14. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes Mellitus and Risk of Alzheimer's Disease and Dementia with Stroke in a Multiethnic Cohort. Am J Epidemiol 2001; 154(7): 635-41.
15. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 2005; 48(12): 2460-9.
16. Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community: The Hisayama Study. Neurology 2011; 77(12): 1126-34.
17. Yaffe K, Blackwell T, Kanaya AM, et al. Diabetes impaired fasting glucose and development of cognitive impairment in older women. Neurology 2004; 63(4): 658-63.
18. Zilkens RR, Davis WA, Spilsbury K, Semmens JB, Bruce DG. Earlier Age of Dementia Onset and Shorter Survival Times in Dementia Patients With Diabetes. Am J Epidemiol 2013; 177(11): 1246-54.
19. Schnaider BM, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004; 63(10): 1902-7.
20. Sanz CM, Hanaire H, Vellas BJ, Sinclair AJ, Andrieu S. Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. Diabet Med 2012; 29(4): 541-8.
21. Fei M, Yan PZ, Ru JM, Ning NL, Lin G. Risk factors for dementia with type 2 diabetes mellitus among elderly people in China. Age Ageing 2013; 42(3): 398-400.
22. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. Br Med J 2004; 328(7439): 548.
23. Xu W, Qiu C, Gatz M, et al. Mid- and Late-Life Diabetes in Relation to the Risk of Dementia: A Population-Based Twin Study. Diabetes 2009; 58(1): 71-7.
24. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. HYpoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301(15): 1565-72.
25. Whitmer RA, Gunderson EP, Barrett-Connor E, et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. Br Med J 2005; 330(7504): 1360.
26. McCutchan JA, Marquie-Beck JA, FitzSimons CA, et al. Role of obesity metabolic variables and diabetes in HIV-associated neurocognitive disorder. Neurology 2012; 78(7): 485-92.
27. Wilbur J, Marquez DX, Fogg L, et al. The Relationship Between Physical Activity and Cognition in Older Latinos. J Gerontol Ser B Psychol Sci Soc Sci 2012; 67(5): 525-34.
28. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64(2): 277-81.
29. Xu WL, Qiu CX, Wahlin Å, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology 2004; 63(7): 1181-6.
30. Fukazawa R, Hanyu H, Sato T, et al. Subgroups of Alzheimer's Disease Associated with Diabetes Mellitus Based on Brain Imaging. Dement Geriatr Cogn Disord 2013; 35(5-6): 280-90.
31. Launer LJ. Diabetes: Vascular or Neurodegenerative: An Epidemiologic Perspective. Stroke 2009; 40(3 suppl 1): S53-5.
32. Gustafson D. Adiposity indices and dementia. Lancet Neurol 2006; 5(8): 713-20.
33. Kodl CT, Seaquist ER. Cognitive Dysfunction and Diabetes Mellitus. Endocr Rev 2008; 29(4): 494-511.
34. Vagelatos NT, Eslick GD. Type 2 Diabetes as a risk factor for Alzheimer's disease: the confounders interactions and neuropathology associated with this relationship. Epidemiol Rev 2014 [Epub ahead of print].
35. Valente T, Gella A, Sole M, Durany N, Unzeta M. Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer's disease and diabetes mellitus. J Neurosci Res 2012; 90(10): 1989-96.
36. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, et al. Long-Term Effect of Diabetes and Its Treatment on Cognitive Function. New Engl J Med 2007; 356(18): 1842-1852.
37. Jabir NR, Kamal MA, Abuzenadah AM, Alama MN, Tabrez S. Alzheimer's and Type 2 diabetes management via common enzyme targeting. CNS Neurol Disord Drug Targets 2014; 13(2): 299-304.
38. Tiribuzi R, Orlacchio A, Crispoltoni L, et al. Lysosomal betagalactosidase and beta-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer's disease and type 2 diabetes mellitus. J Alzheimers Dis 2011; 24(4): 785-97.
39. Yamagishi Y, Hashimoto Y, Niikura T, Nishimoto I. Identification of essential amino acids in Humanin a neuroprotective factor against Alzheimer's disease-relevant insults. Peptides 2003; 24(4): 585-95.
40. Maximov VV, Martynenko AV, Arman IP, Tarantul VZ. Humanin binds MPP8: mapping interaction sites of the peptide and protein. J Pept Sci 2013; 19(5): 301-7.
41. Hashimoto Y, Ito Y, Niikura T, et al. Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein. Biochem Biophys Res Commun 2001; 283(2): 460-8.
42. Jia Y, Lue YH, Swerdloff R, et al. The cytoprotective peptide humanin is induced and neutralizes Bax after pro-apoptotic stress in the rat testis. Andrology 2013; 1(4): 651-9.
43. Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003; 423(6938): 456-61.
44. Bachar AR, Scheffer L, Schroeder AS, et al. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress. Cardiovasc Res 2010; 88(2): 360-6.
45. Zhao ST, Zhao L, Li JH. Neuroprotective Peptide humanin inhibits inflammatory response in astrocytes induced by lipopolysaccharide. Neurochem Res 2013; 38(3): 581-8.
46. Yen K, Lee C, Mehta H, Cohen P. The emerging role of the mitochondrial-derived peptide humanin in stress resistance. J Mol Endocrinol 2013; 50(1): R11-9.
47. Tajima H, Niikura T, Hashimoto Y, et al. Evidence for in vivo production of Humanin peptide a neuroprotective factor against Alzheimer's disease-related insults. Neurosci Lett 2002; 324(3): 227-31.
48. Hashimoto Y, Niikura T, Ito Y, et al. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. J Neurosci 2001; 21(23): 9235-45.
49. Terashita K, Hashimoto Y, Niikura T, et al. Two serine residues distinctly regulate the rescue function of Humanin an inhibiting factor of Alzheimer's disease-related neurotoxicity: functional potentiation by isomerization and dimerization. J Neurochem 2003; 85(6): 1521-38.
50. Mamiya T, Ukai M. [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br J Pharmacol 2001; 134(8): 1597-9.
51. Zhang W, Li Z, Hao J, et al. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice. Pharmacol Biochem Behav 2012; 100(3): 361-9.
52. Zhang W, Du Y, Bai M, et al. S14G-humanin inhibits Abeta1-42 fibril formation disaggregates preformed fibrils and protects against Abeta-induced cytotoxicity in vitro. J Pept Sci 2013; 19(3): 159-65.
53. Wang T, Zhang L, Zhang M, et al. [Gly14]-Humanin reduces histopathology and improves functional outcome after traumatic brain injury in mice. Neuroscience 2013; 23170-81.
54. Wang T, Huang Y, Zhang M, et al.[Gly14]-Humanin offers neuroprotection through glycogen synthase kinase-3beta inhibition in a mouse model of intracerebral hemorrhage. Behav Brain Res 2013; 247: 132-9.
55. Zhao ST, Huang XT, Zhang C, Ke Y. Humanin protects cortical neurons from ischemia and reperfusion injury by the increased activity of superoxide dismutase. Neurochem Res 2012; 37(1): 153-60.
56. Kariya S, Takahashi N, Ooba N, et al. Humanin inhibits cell death of serum-deprived PC12h cells. Neuroreport 2002; 13(6): 903-7.
57. Jung SS, Van Nostrand WE. Humanin rescues human cerebrovascular smooth muscle cells from Abeta-induced toxicity. J Neurochem 2003; 84(2): 266-72.
58. Widmer RJ, Flammer AJ, Herrmann J, et al. Circulating humanin levels are associated with preserved coronary endothelial function. Am J Physiol Heart Circ Physiol 2013; 304(3): H393-7.
59. Caricasole A, Bruno V, Cappuccio I, et al. A novel rat gene encoding a Humanin-like peptide endowed with broad neuroprotective activity. FASEB J 2002; 16(10): 1331-3.
60. Hoang PT, Park P, Cobb LJ, et al. The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice. Metabolism 2010; 59(3): 343-9.
61. Muzumdar RH, Huffman DM, Atzmon G, et al. Humanin: a novel central regulator of peripheral insulin action. PloS ONE 2009; 4(7): e6334.
62. Zhang X, Urbieta-Caceres VH, Eirin A, et al. Humanin prevents intra-renal microvascular remodeling and inflammation in hypercholesterolemic ApoE deficient mice. Life Sci 2012; 91(5-6): 199-206.
63. Tong M, Neusner A, Longato L, et al. Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus non-alcoholic steatohepatitis and Alzheimer's disease. J Alzheimers Dis 2009; 17(4): 827-44.
64. Kuljis RO, Salkovic-Petrisic M. Dementia diabetes Alzheimer's disease and insulin resistance in the brain: progress dilemmas new opportunities and a hypothesis to tackle intersecting epidemics. J Alzheimers Dis 2011; 25(1): 29-41.
65. Bosco D, Fava A, Plastino M, et al. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 2011; 15(9): 1807-21.
66. de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012; 72(1): 49-66.
67. Hildreth KL, Van Pelt RE, Schwartz RS. Obesity insulin resistance and Alzheimer's disease. Obesity 2012; 20(8): 1549-57.
68. de la Monte SM. Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides ER stress and insulin resistance reviewed. J Alzheimers Dis 2012; 30(Suppl 2): S231-49.
69. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance IRS-1 dysregulation and cognitive decline. J Clin Invest 2012; 122(4): 1316-38.
70. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63-80.
71. Watson GS, Craft S. The Role of Insulin Resistance in the Pathogenesis of Alzheimer's Disease. CNS Drugs 2003; 17(1): 27-45.
72. Sridhar GR, Thota H, Allam AR, et al. Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids Health Dis 2006; 528.
73. Smith MA, Rottkamp CA, Nunomura A, et al. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 2000; 1502(1): 139-44.
74. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001; 7(12): 548-54.
75. Deibel MA, Ehmann WD, Markesbery WR. Copper iron and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 1996; 143(1-2): 137-42.
76. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron zinc and copper in the Alzheimer's disease brain: A quantitative metaanalysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol 2011; 94(3): 296-306.
77. Finkelstein DI, Lynch T, Wilkins S, Cherny RA, Bush A. Metals Oxidative Stress and Brain Biology. In: Encyclopedia of Stress (Second Edition); Bruce M, Kloet ER, de Robert R, et al., Eds.; Academic Press: New York 2007; pp. 724-6.
78. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71(2): 621s-9s.
79. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative Stress in Diabetes and Alzheimer's Disease. J Alzheimers Dis 2009; 16(4): 763-74.
80. Moreira PI, Sayre LM, Zhu X, et al. Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. In: Free Radicals and Antioxidant Protocols; Springer 2010; pp. 419-34.
81. Bonda DJ, Wang X, Perry G, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 2010; 59(4): 290-4.
82. Clark TA, Lee HP, Rolston RK, et al. Oxidative stress and its implications for future treatments and management of Alzheimer disease. Intl J Biomed Sci 2010; 6(3): 225.
83. Smith MA, Hirai K, Hsiao K, et al. Amyloid-β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress. J Neurochem 1998; 70(5): 2212-5.
84. Cai Z, Zhao B, Ratka A. Oxidative Stress and β-Amyloid Protein in Alzheimer's Disease. Neuromolecular Med 2011; 13(4): 223-50.
85. Amyloid β -peptide (1-42)-induced Oxidative Stress and Neurotoxicity: Implications for Neurodegeneration in Alzheimer's Disease Brain: A Review. Free Radic Res 2002; 36(12): 1307-13.
86. Zimny A, Bladowska J, Neska M, et al. Quantitative MR evaluation of atrophy as well as perfusion and diffusion alterations within hippocampi in patients with Alzheimer's disease and mild cognitive impairment. Med Sci Monit 2013; 1986-94.
87. Haan MN, Shemanski L, Jaqust WJ, Manolio TA, Kuller L. THe role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999; 282(1): 40-6.
88. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE {varepsilon} 4: the cardiovascular health study cognition study. Arch Neurol 2008; 65(1): 89.
89. Dickson TC, Saunders HL, Vickers JC. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. Neuropathol Appl Neurobiol 1997; 23(6): 483-91.
90. Chargé SB, Esiri MM, Bethune CA, Hansen BC, Clark A. Apolipoprotein E Is Associated With Islet Amyloid And Other Amyloidoses: Implications For Alzheimer's Disease. J Pathol 1996; 179(4): 443-7.
91. Montane J, Klimek-Abercrombie A, Potter KJ, Westwell-Roper C, Bruce Verchere C. Metabolic stress IAPP and islet amyloid. Diabetes Obes Metab 2012; 1468-77.
92. Lei P, Wu W-H, Li R-W, et al. Prevention and promotion effects of apolipoprotein E4 on amylin aggregation. Biochem Biophys Res Commun 2008; 368(2): 414-8.
93. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PloS ONE 2009; 4(11): e7917.
94. Kim I, Lee J, Hong HJ, et al. A relationship between Alzheimer's disease and type 2 diabetes mellitus through the measurement of serum amyloid-beta autoantibodies. J Alzheimers Dis 2010; 19(4): 1371-6.
95. Takeda S. Pathological interaction between diabetes mellitus and Alzheimer's disease. Nihon Shinkei Seishin Yakurigaku Zasshi 2012; 32(5-6): 239-44.
96. Tomita N, Furukawa K, Okamura N, et al. Brain accumulation of amyloid beta protein visualized by positron emission tomography and BF-227 in Alzheimer's disease patients with or without diabetes mellitus. Geriatr Gerontol Int 2013; 13(1): 215-21.
97. Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F, Scheltens P. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 2006; 77(3): 304-7.
98. Götz J, Ittner LM, Lim YA. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 2009; 66(8): 1321-5.
99. Miklossy J, Qing H, Radenovic A, et al. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 2010; 31(9): 1503-15.
100. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368(6473): 756-60.
101. Butler AE, Janson J, Bonner-Weir S, et al. β-Cell Deficit and Increased β -Cell Apoptosis in Humans With Type 2 Diabetes. Diabetes 2003; 52(1): 102-10.
102. Marzban L, Park K, Verchere CB. Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 2003; 38(4): 347.
103. He Y, Fang Z, Yu G. Sortilin-related VPS10 domain containing receptor 1 and Alzheimer's disease-associated allelic variations preferentially exist in female or type 2 diabetes mellitus patients in southern Han Chinese. Psychogeriatrics 2012; 12(4): 215-25.
104. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73(10): 768-74.
105. Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia 2010; 53(1): 10-20.
106. Kamal MA, Greig NH, Priyamvada S, et al. Linking Alzheimer's and type 2 diabetes mellitus via aberrant insulin signalling and inflammation. CNS Neurol Disord Drug Targets 2014; 13(2): 338-46.
107. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73(10): 768-74.
108. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007; 69(6): 1272-6.
109. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-Receptor Antagonist in Type 2 Diabetes Mellitus. N Engl J Med 2007; 356(15): 1517-26.
110. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37(2): 289-305.
111. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37(1): 67-76.
112. Girones X, Guimera A, Cruz-Sanchez CZ, et al. N epsiloncarboxymethyllysine in brain aging diabetes mellitus and Alzheimer's disease. Free Radic Biol Med 2004; 36(10): 1241-7.
113. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71(3): 365-76.
114. Dai Y, Kamal MA. Fighting Alzheimer's disease and type 2 diabetes: Pathological links and treatment strategies. CNS Neurol Disord Drug Targets 2014; 13(2): 271-82.
115. Ain QU, Greig NH, Nawaz MS, Kamal MA. Exploring N1-pfluorobenzyl- cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment. CNS Neurol Disord Drug Targets 2014; 13(2): 197-202.
116. SheikhI A, Ali R, Dar TA, Kamal MA. An overview on potential neuroprotective compounds for management of Alzheimer's Disease. CNS Neurol Disord Drug Targets 2012; 11(8): 1006-11.
117. De Felice FG. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest 2013; 123(2): 531-9.
118. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009; 57(1): 177-9.
119. Zhu CW, Livote EE, Scarmeas N, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. Alzheimers Dement 2013; 9(6): 733-40.
120. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 2013; 6(1): 19-33.
121. Yang Z, Zhou X, Zhang Q. Effectiveness and Safety of Memantine Treatment for Alzheimer's Disease. J Alzheimers Dis 2013; 36(3): 445-58.
122. Cooper GJ. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 2011; 71(10): 1281-320.
123. Gotz J, Ittner LM, Lim YA. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 2009; 66(8): 1321-5.
124. Park TY, Kim SH, Shin YC, et al. Amelioration of neurodegenerative diseases by cell death-induced cytoplasmic delivery of humanin. J Control Release 2013; 166(3): 307-15.
125. de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci 2012; 41582-605.
126. de la Monte SM, Neusner A, Chu J, Lawton M. Epidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease diabetes mellitus and non-alcoholic steatohepatitis. J Alzheimers Dis 2009; 17(3): 519-29.
127. Nedjadi T, Haque A, Alam Q, et al. Genomic Linkage between Alzheimer's Disease and Type 2 Diabetes. CNS Neurol Disord Drug Targets 2014; 13(2): 203-12.
128. Shaik MM, Hua GS, Kamal MA. Epigenomic approach in understanding Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014; 13(2): 283-9.
129. Mirza Z, Ali A, Ashraf GM, et al. Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014; 13(2): 213-25.
130. Priyadarshini M, Kamal MA, Greig NH, et al. Alzheimer's Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase. CNS Neurol Disord Drug Targets 2012; 11(4): 482-9.
131. Dar TA, Sheikh IA, Ganie SA, et al. Molecular linkages between Diabetes and Alzheimer's disease: Current scenario and future prospects. CNS Neurol Disord Drug Targets 2014; 13(2): 290-8.
132. Lue LF, Andrade C, Sabbagh M, Walker D. Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease? Int J Alzheimers Dis 2012; 2012918680.
133. Ahmed F, Ansari JA, Ansari ZE, et al. A molecular bridge: Connecting Diabetes type II and Alzheimer's disease. CNS Neurol Disord Drug Targets 2014; 13(2): 312-21.
134. Jalalian M, Danial AH. Writing for academic journals: A general approach. Electronic Phys 2012; 4(2): 474-6.
135. Jalalian M. Writing an eye-catching and evocative abstract for a research article: A comprehensive and practical approach. Electr Phys 2012; 4(3): 520-4.